rs143141689
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 14P and 1B. PM1PM2PM5PP5_Very_StrongBS1_Supporting
The ENST00000371568.8(ORC1):c.314G>A(p.Arg105Gln) variant causes a missense change. The variant allele was found at a frequency of 0.000297 in 1,614,036 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R105W) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000371568.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ORC1 | NM_004153.4 | c.314G>A | p.Arg105Gln | missense_variant | 4/17 | ENST00000371568.8 | NP_004144.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ORC1 | ENST00000371568.8 | c.314G>A | p.Arg105Gln | missense_variant | 4/17 | 1 | NM_004153.4 | ENSP00000360623 | P1 | |
ORC1 | ENST00000371566.1 | c.314G>A | p.Arg105Gln | missense_variant | 4/17 | 1 | ENSP00000360621 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000158 AC: 24AN: 152202Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000954 AC: 24AN: 251480Hom.: 0 AF XY: 0.0000662 AC XY: 9AN XY: 135910
GnomAD4 exome AF: 0.000312 AC: 456AN: 1461834Hom.: 0 Cov.: 32 AF XY: 0.000285 AC XY: 207AN XY: 727224
GnomAD4 genome AF: 0.000158 AC: 24AN: 152202Hom.: 0 Cov.: 32 AF XY: 0.000121 AC XY: 9AN XY: 74350
ClinVar
Submissions by phenotype
Meier-Gorlin syndrome 1 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 30, 2021 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 27, 2011 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | The ORC1 c.314G>A (p.Arg105Gln) missense variant has been reported in two studies in which it is found in a total of seven individuals with Meier-Gorlin syndrome, including in one in a homozygous state and in six (including two siblings) in a compound heterozygous state with a truncating variant or splice acceptor site variant as the second allele (Bicknell et al. 2011; de Munnik et al. 2012). Control data are unavailable for this variant, which is reported at a frequency of 0.00047 in the European American population of the Exome Sequencing Project. Functional studies suggest that the p.Arg105Gln variant abolishes the ability of Orc1 to inhibit Cyclin E-CDK2 kinase activity (Hossain and Stillman 2012) and reduces DNA binding affinity leading to impaired nucleosome interaction (Zhang et al. 2015). Based on the evidence, the p.Arg105Gln variant is classified as pathogenic for Meier-Gorlin syndrome. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Sep 07, 2021 | The sequence change, c.314G>A, in exon 4 results in an amino acid change, p.Arg105Gln. This sequence change has been previously described in the homozygous and compound heterozygous states in individuals and families with ORC1-related Meier-Gorlin syndrome (PMIDs: 21358632, 21358631, 22333897). This sequence change has been described in the gnomAD database with a low frequency of 0.023% in non-Finnish European subpopulation only (dbSNP rs143141689). The p.Arg105Gln change affects a highly conserved amino acid residue located in the BAH domain of the ORC1 protein. Functional studies indicates p.Arg105Gln disrupts the function of the ORC1 protein (PMID: 22855792, 25689043). Collectively this evidence suggests p.Arg105Gln is pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 19, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 105 of the ORC1 protein (p.Arg105Gln). This variant is present in population databases (rs143141689, gnomAD 0.02%). This missense change has been observed in individuals with Meier-Gorlin syndrome (PMID: 21358631, 21358632). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 30232). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ORC1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects ORC1 function (PMID: 22855792). For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jul 19, 2022 | Published functional studies demonstrate reduced ORC1 DNA binding affinity, leading to impaired ORC1-nucleosome reaction and a defect in regulation of centriole and centrosome copy numbers (Zhang et al., 2015; Hossain et al., 2012); This variant is associated with the following publications: (PMID: 22855792, 23516378, 30609409, 34426522, 14564153, 31980526, 26323792, 33477564, 11477602, 21358632, 23023959, 33761311, 21358633, 22333897, 21358631, 25689043) - |
Meier-Gorlin syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Apr 13, 2016 | The p.Arg105Gln variant in ORC1 has been reported in at least 5 individuals (1 h omozygous and 4 compound heterozygous with other disease-associated variants) wi th clinical features of Meier-Gorlin syndrome (Bicknell 2011, de Munnik 2012). T his variant has also been identified in 10/121,412 of chromosomes by the Exome A ggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs143141689). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. In vitro functi onal studies provide some evidence that the p.Arg105Gln variant may impact prote in function (Bicknell 2011, Hossain 2012, Zhang 2015). In summary, this variant meets our criteria to be classified as pathogenic for Meier-Gorlin syndrome in a n autosomal recessive manner based upon its co-occurrence with disease-causing v ariants in affected individuals, low frequency in control populations and functi onal evidence. - |
ORC1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 07, 2024 | The ORC1 c.314G>A variant is predicted to result in the amino acid substitution p.Arg105Gln. This variant was reported in the homozygous and compound heterozygous state in individuals with Meier-Gorlin syndrome (Bicknell et al. 2011. PubMed ID: 21358633; Bicknell et al. 2011. PubMed ID: 21358632; Hossain et al. 2012. PubMed ID: 22855792; Zhang et al. 2015. PubMed ID: 25689043). This variant is reported in 0.023% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at